MediWound (MDWD) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12 month price targets for MediWound's stock. Their MDWD share price forecasts range from $25.00 to $36.00. On average, they anticipate the company's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 172.6% from the stock's current price.
View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts.

MediWound's stock was trading at $13.49 at the beginning of 2023. Since then, MDWD shares have decreased by 21.1% and is now trading at $10.64.
View the best growth stocks for 2023 here.

MediWound saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 50,800 shares, an increase of 23.6% from the August 31st total of 41,100 shares. Based on an average daily volume of 17,900 shares, the short-interest ratio is presently 2.8 days. Currently, 0.8% of the company's shares are sold short.
View MediWound's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our MDWD earnings forecast.

MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings results on Tuesday, August, 15th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.41) by $0.51. The biopharmaceutical company had revenue of $4.77 million for the quarter, compared to the consensus estimate of $4.19 million. MediWound had a negative net margin of 55.53% and a negative trailing twelve-month return on equity of 71.45%.

MediWound's stock reverse split before market open on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDWD stock can currently be purchased for approximately $10.64.

MediWound (NASDAQ:MDWD) has a market capitalization of $97.99 million and generates $26.50 million in revenue each year. The biopharmaceutical company earns $-19,600,000.00 in net income (profit) each year or ($2.4297) on an earnings per share basis.

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The official website for the company is www.mediwound.com. The biopharmaceutical company can be reached via phone at 972779714100, via email at afields@lhai.com, or via fax at 972-77-971-4111.